Lyon (France) — genOway (ALTERNEXT-NYSE EURONEXT: ALGEN; ISIN: FR0004053510), the biotechnology company dedicated to the development of genetically modified animal models, today announces strong growth of its business with major Japanese biopharmaceutical companies.

The three Japanese biopharmaceutical companies, now customers of genOway, rank among the top ten of the nation’s biopharmaceutical industry. The amount of the active contracts just exceeded €400,000.

These agreements cover the development and delivery of genetically modified animal models and particularly humanized models dedicated to pharmaceutical compound testing.

Other contractual details were not disclosed.

Alexandre Fraichard, CEO of genOway, declared: «Japanese biopharmaceutical industry is beginning to show signs of recovery. We were able to drop back on the market since the second half of 2009 and are very pleased that three of the largest Japanese biopharmaceutical companies now make use of our services and added value solutions. It is very important for us to attend sustainably this market, the second in size after the United States. In fact, we are very confident in signing several contracts in Japan in the coming trimesters. » About genOway genOway (ALTERNEXT-NYSE: ALGEN) is a biotechnology company developing genetically modified and high value-added research models for the bio-pharmaceutical, chemical, agrochemical and food industry as well as for academic research. With highly qualified scientific personnel, the company has a work force of 60 people and operates in over 22 countries in Europe, Asia and North America, supplying more than 285 research institutes and bio-pharmaceutical companies. genOway is a leader in its market in terms of both size and customer portfolios. The company’s development is founded upon both a broad and exclusive technology platform as well as strong intellectual property rights combining patents and licensing agreements. Taking advantage of the global trend towards outsourcing the production of genetically modified research models, genOway has signed many contracts with leaders of the pharmaceutical industry (Pfizer, Bayer, Boehringer Ingelheim, etc.), and with the most prestigious academic research centers (King’s College and the University of Manchester, in England; Duke University and the National Institutes of Health, in the United States; the Institut Pasteur, in France; NGFN and the Max Planck Institutes, in Germany, etc.).

To strengthen its technological position and benefit from worldwide business partners, genOway has signed strategic alliances with leading companies in their field: Charles River Laboratories (NYSE: CRL, a world leader in supplying laboratory animals), Invitrogen (NASDAQ: IVGN, world leader in supplying molecular biology reagents). For more information please visit www.genoway.com.

Press relations: Marie Norbert – genOway – info@genoway.com Contact for investors: Gaëlle Lebel , CFO – info@genoway.com Milestones – press & investor relations: Bruno Arabian / Jacques-Olivier Costa Tel.: +33 (0)1 75 44 87 40 / 42 – E-mails: barabian@milestones.fr / jocosta@milestones.fr Warning: This press release contains certain prospective statements, either express or implied, concerning genOway and its activities. These statements rely on certain risks, either known or unknown, uncertainties or other factors, that may lead to genOway’s actual results, financial condition, performance or achievements differing significantly from the results, financial condition, performance or achievements expressed or implied in these prospective statements. genOway is issuing this press release on the present date and is not committed to updating the prospective statements contained therein, either as a result of new information, future events or any other occurrence. For a detailed description of the types of risks or uncertainties likely to cause a difference between genOway’s actual results, financial condition, performance or achievements and those contained in the prospective statements, please refer to the section on “Risk Factors” in the prospectus available on the genOway website: www.genoway.com.